Limiting RyR2 Open Time Prevents Alzheimer’s Disease-Related Neuronal Hyperactivity and Memory Loss but Not β-Amyloid Accumulation
Open accessThe DOI matches its Crossref record; 23 of the 23 references it cites were found in a registry or an index.
Abstract
current, a well-known neuronal excitability control that is downregulated in AD. Pharmacologically limiting RyR2 open time with the R-carvedilol enantiomer (but not racemic carvedilol) prevents and rescues neuronal hyperactivity, memory impairment, and neuron loss even in late stages of AD. These AD-related deficits are prevented even with continued β-amyloid accumulation. Thus, limiting RyR2 open time may be a hyperactivity-directed, non-β-amyloid-targeted anti-AD strategy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Effect of Carvedilol on Morbidity and Mortality in Patients with Chronic Heart Failure
Packer, M., Bristow, M. R., Cohn, J. N., Colucci, W. S., Fowler, M. B., Gilbert, E. M., & Shusterman, N. H. (1996) · New England Journal of Medicine · doi:10.1056/nejm199605233342101 · Cited by 4,649
Oakley, H., Cole, S. L., Logan, S., Maus, E., Shao, P., Craft, J., Guillozet-Bongaarts, A., Ohno, M., Disterhoft, J., Van Eldik, L., et al. (2006) · The Journal of Neuroscience · doi:10.1523/jneurosci.1202-06.2006 · Cited by 3,530 · cited 8×
“Adult genetically engineered mice, 5xFAD+/− (Oakley et al., 2006), RyR2-E4872Q+/− (EQ+/−) (Chen et al.”
BackgroundMethodResultInfluentialThe antibody aducanumab reduces Aβ plaques in Alzheimer’s disease
Sevigny, J., Chiao, P., Bussière, T., Weinreb, P. H., Williams, L., Maier, M., Dunstan, R., Salloway, S., Chen, T., Ling, Y., et al. (2016) · Nature · doi:10.1038/nature19323 · Cited by 3,059 · cited 1×
“Hence, the dominating therapeutic anti-AD strategy has been reducing Aβ depositions (Demattos et al., 2012; Kennedy et al., 2016; Sevigny et al., 2016).”
BackgroundKarran, E., Mercken, M., & Strooper, B. D. (2011) · Nature Reviews Drug Discovery · doi:10.1038/nrd3505 · Cited by 2,188 · cited 3×
“amyloid (Aβ) plaques in the brain (Berridge, 2010; Hardy and Selkoe, 2002; Karran et al., 2011).”
BackgroundAPP Processing and Synaptic Function
Kamenetz, F., Tomita, T., Hsieh, H., Seabrook, G., Borchelt, D., Iwatsubo, T., Sisodia, S., & Malinow, R. (2003) · Neuron · doi:10.1016/s0896-6273(03)00124-7 · Cited by 1,644 · cited 1×
“Importantly, neuronal hyperactivity itself can trigger release of endogenous soluble Aβ (Cirrito et al., 2005; Kamenetz et al., 2003; Yamamoto et al., 2015).”
Synaptic Activity Regulates Interstitial Fluid Amyloid-β Levels In Vivo
Cirrito, J. R., Yamada, K. A., Finn, M. B., Sloviter, R. S., Bales, K. R., May, P. C., Schoepp, D. D., Paul, S. M., Mennerick, S., & Holtzman, D. M. (2005) · Neuron · doi:10.1016/j.neuron.2005.10.028 · Cited by 1,265 · cited 1×
“Importantly, neuronal hyperactivity itself can trigger release of endogenous soluble Aβ (Cirrito et al., 2005; Kamenetz et al., 2003; Yamamoto et al., 2015).”
Trial of Solanezumab for Mild Dementia Due to Alzheimer’s Disease
Honig, L. S., Vellas, B., Woodward, M., Boada, M., Bullock, R., Borrie, M., Hager, K., Andreasen, N., Scarpini, E., Liu-Seifert, H., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1705971 · Cited by 1,049 · cited 2×
“However, achieving a sufficient Aβ reduction to prevent induction of neuronal hyperactivity and, consequently, AD progression may be an obstacle, which explains, in part, the failure of some recent Aβ-targeted clinical trials (Chakroborty and Stutzmann, 2014; Honig et al., 2018; Karran et al., 2011).”
BackgroundIncreased hippocampal activation in mild cognitive impairment compared to normal aging and AD
Dickerson, B. C., Salat, D. H., Greve, D. N., Chua, E. F., Rand-Giovannetti, E., Rentz, D. M., Bertram, L., Mullin, K., Tanzi, R. E., Blacker, D., et al. (2005) · Neurology · doi:10.1212/01.wnl.0000171450.97464.49 · Cited by 910 · cited 1×
“Compelling evidence points to neuronal hyperactivity as an early primary neuronal dysfunction in human AD patients as well as animal models of AD (Busche et al., 2008, 2012; Busche and Konnerth, 2015; Dickerson et al., 2005; Keskin et al., 2017; Lerdkrai et al., 2018; Nuriel et al., 2017; O’Brien et al., 2010; Stargar…”
BackgroundBusche, M. A., Chen, X., Henning, H. A., Reichwald, J., Staufenbiel, M., Sakmann, B., & Konnerth, A. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1206171109 · Cited by 715
A vicious cycle of β amyloid−dependent neuronal hyperactivation
Zott, B., Simon, M. M., Hong, W., Unger, F., Chen-Engerer, H.-J., Frosch, M. P., Sakmann, B., Walsh, D. M., & Konnerth, A. (2019) · Science · doi:10.1126/science.aay0198 · Cited by 640 · cited 7×
“Compelling evidence points to neuronal hyperactivity as an early primary neuronal dysfunction in human AD patients as well as animal models of AD (Busche et al., 2008, 2012; Busche and Konnerth, 2015; Dickerson et al., 2005; Keskin et al., 2017; Lerdkrai et al., 2018; Nuriel et al., 2017; O’Brien et al., 2010; Stargar…”
BackgroundMethodInfluential
Cited by
Ca2+ Dyshomeostasis Disrupts Neuronal and Synaptic Function in Alzheimer’s Disease
McDaid, J., Mustaly-Kalimi, S., & Stutzmann, G. E. (2020) · Cells · doi:10.3390/cells9122655 · Cited by 73
Mustaly-Kalimi, S., Gallegos, W., Marr, R. A., Gilman-Sachs, A., Peterson, D. A., Sekler, I., & Stutzmann, G. E. (2022) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2211999119 · Cited by 55
Zhang, H., Knight, C., Chen, S. R. W., & Bezprozvanny, I. (2023) · The Journal of Neuroscience · doi:10.1523/jneurosci.1820-22.2022 · Cited by 32
Self-citationLi, Z., Cao, Y., Pei, H., Ma, L., Yang, Y., & Li, H. (2023) · Frontiers in Neuroscience · doi:10.3389/fnins.2023.1158204 · Cited by 30
Wickline, J. L., Smith, S., Shin, R., Odfalk, K., Sanchez, J., Javors, M., Ginsburg, B., & Hopp, S. C. (2023) · Neuropharmacology · doi:10.1016/j.neuropharm.2023.109454 · Cited by 2
Metadata
- Authors
- Yao, J., Sun, B., Institoris, A., Zhan, X., Guo, W., Song, Z., Liu, Y., Hiess, F., Boyce, A. K. J., Ni, M., Wang, R., ter Keurs, H., Back, T. G., Fill, M., Thompson, R. J., Turner, R. W., Gordon, G. R., & Chen, S. R. W.
- Venue
- Cell Reports
- Publisher
- Elsevier BV
- Published
- 2020-09
- Volume
- 32
- Issue
- 12
- Pages
- 108169
- ISSN
- 2211-1247 (ISSN-L)
- OpenAlex
- W3088306168
- Cited by
- 65
- References
- 23
- FWCI
- 4.53
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.